Vidora, 3 mg+0.03 mg 28 pcs

Vidora is a microdose combined monophasic hormonal contraceptive drug containing ethinyl estradiol and drospirenone. The contraceptive effect of the drug is based on the interaction of various factors, the most important of which are inhibition of ovulation, increasing the viscosity of the cervical secretion, making it impermeable to sperm.

When used correctly, the Perl Index (a measure of the number of pregnancies in 100 women using the contraceptive over the course of a year) is less than 1. If the pill is missed or used incorrectly, the Perl index may increase.

Drospirenone also has antiandrogenic and weak anti-mineralocorticoid properties at the therapeutic dose. Drospirenone has no estrogenic, glucocorticosteroid or antiglucocorticosteroid activity and has a pharmacological profile similar to that of natural progesterone.

With anti-androgenic activity the drug promotes reduction of sebum production and improvement of the clinical course in women with acne (acne vulgaris), which should be considered when choosing a contraceptive drug, especially for women with hormone-dependent fluid retention and for women with acne and seborrhea.

In combination with ethinylestradiol, it improves the lipid profile and increases the concentration of high-density lipoproteins.

Limiting menstrual bleeding, the drug helps to reduce the severity of pain and the volume of menstrual bleeding, thereby reducing one of the risk factors for iron deficiency anemia. In addition, there is evidence that the use of combined oral contraceptives (OCs) reduces the risk of endometrial cancer and ovarian cancer.

Indications

Oral contraception

Active ingredient

Composition

1 yellow coated tablet contains drospirenone 3.0 mg and ethinyl estradiol 0.03 mg

excipients:

lactose,

corn starch,

corn starch,
.

crospovidonePlan XL-10 crospovidonePlan XL,

povidone K-30,

polysorbate 80,

magnesium stearate,

Opadry® yellow (polyethylene glycol, polyvinyl alcohol, titanium dioxide (E 171),

talk,

Iron oxide yellow (E172)).

1 white coated tablet (placebo) contains

excipients:

lactose,

povidone K-30,

magnesium stearate, Opadry® II white (polyvinyl alcohol (hydrolyzed part), titanium dioxide (E 171),

macrogol 3350,

talc (E 553b)).

How to take, the dosage

The tablets should be taken every day at the same time, with a little liquid if necessary, according to the order listed on the blister pack.

The tablets are taken continuously.

One tablet is taken daily for 28 consecutive days.

The pills in each successive pack start the day after the last pill in the previous pack is taken.

The withdrawal bleeding usually begins 2 to 3 days after starting the placebo pills (last line) and may not end until the pills from the next pack are taken.

Overdose

There is no experience with drospirenone/ethinylestradiol overdose by this time.

Based on general experience with combined oral contraceptives, the symptoms that can be observed with an overdose of the active pills are nausea, vomiting, and, in young girls, minor bleeding from the vagina.

There are no antidotes and further treatment must be symptomatic.

Similarities